Applied Dna Sciences Inc (NASDAQ:APDN)’s traded shares stood at 2.04 million during the last session, with the company’s beta value hitting 0.18. At the close of trading, the stock’s price was $0.55, to imply a decrease of -5.27% or -$0.03 in intraday trading. The APDN share’s 52-week high remains $177.00, putting it -32081.82% down since that peak but still an impressive -1.82% since price per share fell to its 52-week low of $0.56.

Analysts have given a consensus recommendation of Buy for Applied Dna Sciences Inc (APDN), translating to a mean rating of 3.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give APDN a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy.

Applied Dna Sciences Inc (NASDAQ:APDN) trade information

After registering a -5.27% downside in the last session, Applied Dna Sciences Inc (APDN) has traded red over the past five days. The 5-day price performance for the stock is -32.14%, and -36.36% over 30 days. With these gigs, the year-to-date price performance is -94.61%.

The extremes give us $1.5 and $1.5 for target low and target high price respectively. As such, APDN has been trading -172.73% off suggested target high and -172.73% from its likely low.

APDN Dividends

Applied Dna Sciences Inc has its next earnings report out in June. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

We also have Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and Fidelity Concord Street Trust-Fidelity Series Total Market Index Fund as the top two Mutual Funds with the largest holdings of the Applied Dna Sciences Inc (APDN) shares. Going by data provided on Mar 31, 2025 , Fidelity Concord Street Trust-Fidelity Extended Market Index Fund holds roughly 6.63 shares. This is just over 0.10% of the total shares, with a market valuation of $3646.0. Data from the same date shows that the other fund manager holds a little less at 1.41, or 0.02% of the shares, all valued at about 774.0.